- Home
- STI vs CLDI Comparison
STI vs CLDI Comparison
Compare STI & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- CLDI
- Stock Information
- Founded
- STI 2014
- CLDI 2014
- Country
- STI United States
- CLDI United States
- Employees
- STI N/A
- CLDI N/A
- Industry
- STI
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STI
- CLDI Health Care
- Exchange
- STI NYSE
- CLDI Nasdaq
- Market Cap
- STI 9.5M
- CLDI 10.2M
- IPO Year
- STI N/A
- CLDI N/A
- Fundamental
- Price
- STI $3.73
- CLDI $0.27
- Analyst Decision
- STI
- CLDI Strong Buy
- Analyst Count
- STI 0
- CLDI 1
- Target Price
- STI N/A
- CLDI $10.00
- AVG Volume (30 Days)
- STI 74.6K
- CLDI 586.3K
- Earning Date
- STI 08-12-2025
- CLDI 08-12-2025
- Dividend Yield
- STI N/A
- CLDI N/A
- EPS Growth
- STI N/A
- CLDI N/A
- EPS
- STI 6.72
- CLDI N/A
- Revenue
- STI N/A
- CLDI N/A
- Revenue This Year
- STI N/A
- CLDI N/A
- Revenue Next Year
- STI N/A
- CLDI N/A
- P/E Ratio
- STI $0.56
- CLDI N/A
- Revenue Growth
- STI N/A
- CLDI N/A
- 52 Week Low
- STI $2.94
- CLDI $0.28
- 52 Week High
- STI $55.00
- CLDI $3.89
- Technical
- Relative Strength Index (RSI)
- STI 49.92
- CLDI 29.88
- Support Level
- STI $3.22
- CLDI $0.31
- Resistance Level
- STI $3.93
- CLDI $0.32
- Average True Range (ATR)
- STI 0.27
- CLDI 0.03
- MACD
- STI 0.12
- CLDI -0.00
- Stochastic Oscillator
- STI 57.61
- CLDI 8.50
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a IP leader in both the high-capacity anode and the high-energy solid-state battery.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.